EXAS (Cologuard) יחס שווי שוק לשווי בספרים

Exact Sciences (EXAS) leverages an efficient sample express delivery network to mitigate the risks of rare reagent supply chain disruptions. The price-to-book ratio trend visualizes this balance, where the 8.33 metric reflects current asset value dynamics. Stable domestic demand for diagnostics is coupled with breakthrough DNA tests that radically improve patient recovery odds through early cancer detection.

The high cost of Exact Sciences (EXAS) robotic complexes and AI systems is reflected in the current price-to-book ratio, linking the market valuation to the capital intensity of the diagnostics business. This indicator is calculated as the ratio of market capitalization to net assets, measuring the investor premium over book value and determining the capital margin of safety when assessing the asset's fundamental overbought status.